Lipid disorders

>

Latest News

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia /image credit ©muhammed/stock.adobe.com
FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

August 1st 2025

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C
FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

February 10th 2025

Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns /Image Seth J Baum
Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns

September 25th 2024

Dyslipidemia in American Indian Youth: Daily Dose / image credit: ©New Africa/AdobeStock
Dyslipidemia in American Indian Youth: Daily Dose

March 15th 2024

New Data Show High Prevalence of Dyslipidemia in American Indian Youth / Image credit: ©hywards/AdobeStock
New Data Show High Prevalence of Dyslipidemia in American Indian Youth

March 8th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.